Circulating concentrations of GDF11 are positively associated with TSH levels in humans by Gomez-Ambrosi, J. (Javier) et al.
Journal of
Clinical Medicine
Article
Circulating Concentrations of GDF11 are Positively
Associated with TSH Levels in Humans
Juan Añón-Hidalgo 1, Victoria Catalán 1,2,3, Amaia Rodríguez 1,2,3 , Beatriz Ramírez 1,2,3,
Adrián Idoate-Bayón 1, Camilo Silva 2,3,4, Carmen Mugueta 5, Juan C. Galofré 4,
Javier Salvador 2,4, Gema Frühbeck 1,2,3,4 and Javier Gómez-Ambrosi 1,2,3,*
1 Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain;
janon@alumni.unav.es (J.A.-H.); vcatalan@unav.es (V.C.); arodmur@unav.es (A.R.);
bearamirez@unav.es (B.R.); aidoate.10@alumni.unav.es (A.I.-B.); gfruhbeck@unav.es (G.F.)
2 CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III,
31008 Pamplona, Spain; csilvafr@unav.es (C.S.); jsalvador@unav.es (J.S.)
3 Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA),
31008 Pamplona, Spain
4 Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, 31008 Pamplona, Spain;
jcgalofre@unav.es
5 Department of Biochemistry, Clínica Universidad de Navarra, 31008 Pamplona, Spain; cmugueta@unav.es
* Correspondence: jagomez@unav.es; Tel.: +34-948-42-56-00 (ext. 806567)
Received: 16 May 2019; Accepted: 18 June 2019; Published: 19 June 2019


Abstract: Growth differentiation factor 11 (GDF11) is a member of the transforming growth factor
(TGF)-β superfamily which declines with age and has been proposed as an anti-aging factor with
regenerative effects in skeletal muscle in mice. However, recent data in humans and mice are
conflicting, casting doubts about its true functional actions. The aim of the present study was to
analyze the potential involvement of GFD11 in energy homeostasis in particular in relation with
thyroid hormones. Serum concentrations of GDF11 were measured by enzyme-linked immunosorbent
assay (ELISA) in 287 subjects. A highly significant positive correlation was found between GDF11
and thyroid-stimulating hormone (TSH) concentrations (r = 0.40, p < 0.001). Neither resting
energy expenditure (REE) nor REE per unit of fat-free mass (REE/FFM) were significantly correlated
(p > 0.05 for both) with GDF11 levels. In a multiple linear regression analysis, the model that best
predicted logGDF11 included logTSH, leptin, body mass index (BMI), age, and C-reactive protein
(logCRP). This model explained 37% of the total variability of logGDF11 concentrations (p < 0.001),
with only logTSH being a significant predictor of logGDF11. After segregating subjects by TSH levels,
those within the low TSH group exhibited significantly decreased (p < 0.05) GDF11 concentrations
as compared to the normal TSH group or the high TSH group. A significant correlation of GDF11
levels with logCRP (r = 0.19, p = 0.025) was found. GDF11 levels were not related to the presence
of hypertension or cardiopathy. In conclusion, our results show that circulating concentrations of
GDF11 are closely associated with TSH concentrations and reduced in subjects with low TSH levels.
However, GDF11 is not related to the regulation of energy expenditure. Our data also suggest that
GDF11 may be involved in the regulation of inflammation, without relation to cardiac function.
Further research is needed to elucidate the role of GDF11 in metabolism and its potential involvement
in thyroid pathophysiology.
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1. Introduction
Thyroid hormones are involved in the regulation of basal metabolic rate and are active players
in many physiological processes, such as growth, development, as well as energy expenditure [1].
It has been shown that basal metabolism is very sensitive to thyroid hormones, with the dysregulation
of the thyroid axis leading to marked alterations in energy balance [1,2]. The thyroid gland is
regulated by the hypothalamic thyrotropin-releasing hormone, which regulates the secretion of
thyroid-stimulating hormone (TSH) from the pituitary gland [2]. Activation of thyroxine (T4),
to the active form, triiodothyronine (T3), by 5′-deiodinase type 2 is a key cellular mechanism in the
regulation of metabolism in peripheral tissues [2]. Thyroid hormone signaling takes place peripherally,
mostly in the liver, white and brown adipose tissues, but also centrally, in the hypothalamus [1,2].
Thyroid hormones directly stimulate energy expenditure changing the functionality and increasing the
expression of genes involved in thermogenesis, such as uncoupling protein 1, in peripheral tissues
such as skeletal muscle and brown adipose tissue (BAT), but also through central actions [3].
The transforming growth factor (TGF)-β superfamily of signaling proteins encompasses more
than 30 members exerting pleiotropic functions through similar pathways of signal transduction [4–6].
At least three subfamilies have been described to date: TGF-βs, bone morphogenetic proteins
(BMPs)/growth differentiation factors (GDFs), and activins/inhibins [5,6]. GDF11 is expressed in
many tissues and organs including skeletal muscle, heart, pancreas, kidney, intestine, developing
nervous system, olfactory system, as well as in the retina [7]. GDF11 levels have been shown to
decline with aging in mice losing their reported actions to promote skeletal muscle regeneration [8].
However, further studies have found contradictory results showing that GDF11 may produce skeletal
muscle atrophy rather than regeneration [6,7]. In humans, results regarding circulating levels of
GDF11 are conflicting, showing a decrease [9], an increase or a trend to an increase [10,11], or no
change [11,12] with aging. We have recently shown that GDF11 levels decline with aging in humans
with no influence on skeletal muscle mass [13]. Recent data suggest that another member of the TGF-β
superfamily, GDF15, correlates with thyroid hormones being elevated in patients with hyperthyroidism,
and that the treatment with thyroid hormone increases the expression of GDF15 in BAT in mice [14].
Therefore, we hypothesized that GDF11 could be involved in energy expenditure and associated with
thyroid hormones.
We aimed to investigate in humans the relation of GDF11 with thyroid hormones and energy
expenditure in a large cohort of well-characterized subjects. In addition, we studied the levels of
GDF11 in individuals with high, normal, or low levels of TSH.
2. Materials and Methods
2.1. Study Participants
We conducted a cross-sectional analysis of 287 patients (121 men and 166 women) aged 18–79 years,
with similar socioeconomic characteristics, including patients visiting the Department of Endocrinology
and Nutrition of the Clínica Universidad de Navarra (Pamplona, Spain) for weight loss treatment as
well as hospital and University staff undergoing an annual routine health check-up. In a subsequent
analysis, individuals with complete thyroid profile (n = 128) were classified according to TSH
concentrations in high TSH (TSH > 4.7 µU/mL), normal TSH (TSH between 0.5–4.7 µU/mL), or low
TSH (TSH < 0.5 µU/mL) based on the normal reference values [15]. Participants underwent a
clinical assessment including medical history, physical examination, body composition analysis,
and comorbidity evaluation performed by a multidisciplinary consultation team. Individuals with
signs of infection were excluded. The experimental design was approved by the Research Ethics
Committee of the University of Navarra (protocol 2017.121) and the study was performed in accordance
with the ethical standards as laid down in the Declaration of Helsinki and its later amendments.
Volunteers gave their informed consent to participate in the study.
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2.2. Anthropometry and Resting Energy Expenditure
The anthropometric and body composition determinations as well as the blood extraction were
performed in a single day. Height was measured to the nearest 0.1 cm with a Holtain stadiometer
(Holtain Ltd., Crymych, UK), while body weight was measured with a calibrated electronic scale to the
nearest 0.1 kg with subjects wearing a swimming suit and cap. Body mass index (BMI) was calculated
as weight in kg divided by the square of height in meters. Waist circumference was measured at
the midpoint between the iliac crest and the rib cage on the midaxillary line. Blood pressure was
measured after a 5-minute rest in the semi-sitting position with a sphygmomanometer. Blood pressure
was determined at least three times at the right upper arm and the mean was used in the analyses.
Body density was estimated by air displacement plethysmography (Bod-Pod®, Life Measurements,
Concord, CA, USA). Percentage of body fat was estimated from body density using the Siri equation as
previously described [16]. Fat-free mass (FFM) index (FFMI) was calculated as FFM in kg divided by
the square of height in meters [17]. Resting energy expenditure (REE) was measured through indirect
calorimetry (Vmax29, SensorMedics Corporation, Yorba Linda, CA, USA) [18].
2.3. Serum Biochemistry
Blood samples were collected after an overnight fast in the morning in order to avoid potential
confounding influences due to hormonal rhythmicity. Plasma glucose was analyzed by an automated
analyzer (Roche/Hitachi Modular P800, Basel, Switzerland) as previously described [19]. Insulin was
measured by means of enzyme-amplified chemiluminescence assay (IMMULITE 2000, Siemens AG,
Erlangen, Germany). The homeostatic model assessment (HOMA) was used as an indirect measure of
insulin resistance. Total cholesterol and triglyceride concentrations were determined by enzymatic
spectrophotometric methods (Roche, Basel, Switzerland). Serum high-density lipoprotein cholesterol
(HDL-C) was quantified by a colorimetric method in a Beckman Synchron® CX analyzer (Beckman
Instruments, Ltd., Bucks, UK). Low-density lipoprotein (LDL-C) was calculated by the Friedewald
formula. High-sensitivity C-reactive protein (CRP) was measured using the Tina-quant CRP (Latex)
ultrasensitive assay (Roche). Uric acid and creatinine were measured by enzymatic tests (Roche)
in an automated analyzer (Roche/Hitachi Modular P800, Basel, Switzerland). TSH, free thyroxine
(fT4), and free triiodothyronine (fT3) concentrations were measured by an electro-chemiluminescence
immunoassay (ECLIA) using Roche Elecsys® E170 immunoassay analyzer (Roche, Basel, Switzerland).
Leptin levels were quantified by a double-antibody radioimmunoassay (RIA) method (Linco Research,
Inc., St. Charles., MO, USA) as previously described [18,20]; intra- and interassay coefficients of
variation were 5.0 and 4.5%, respectively. Thyroid peroxidase (anti-TPO) and thyroglobulin (anti-TG)
antibodies were measured by enzyme-linked immunosorbent assay (ELISA) (QUANTA Lite®, Inova
Diagnostics, San Diego, CA, USA). Serum GDF11 concentrations were determined using a validated
ELISA kit (Human GDF11 ELISA kit, E01G0124, BlueGene Biotech, Shanghai, China) with intra- and
interassay coefficients of variation being 5.5 and 7.8%, respectively. According to the manufacturer,
no cross reactivity has been observed with any other analogue.
2.4. Cardiac Function
Resting electrocardiogram (ECG) in individuals with thyroid profile was recorded on a PageWriter
TC20 Cardiograph (Philips Medical Systems, Andover, MA, USA). In a subset of patients (n = 40),
Doppler ultrasound measurements were obtained with a Philips SONOS 7500 Echocardiography
System (Philips Medical Systems, Andover, MA, USA).
2.5. Statistical Analysis
Data are presented as mean ± SD unless otherwise indicated. Normal distribution was assessed by
Kolmogorov–Smirnov test. Differences between groups were analyzed by one-way ANOVA followed
by Fisher’s least significant difference (LSD) tests or two-tailed unpaired Student’s t tests, as appropriate.
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Correlations between two variables were computed by Pearson’s correlation coefficients (r). Multivariate
linear regression analysis was conducted for the dependent variable logGDF11 including the variables
which showed a significant correlation with logGDF11 as independent variables. The calculations
were performed using SPSS 23 (SPSS, Chicago, IL, USA) and GraphPad Prism 6 (GraphPad Software,
Inc., La Jolla, CA, USA). A p value lower than 0.05 was considered statistically significant.
3. Results
Anthropometric and biochemical characteristics of the individuals included in the study are shown
in Table 1. From the whole cohort, 121 (42%) were males and 166 (58%) were females. No significant
differences regarding gender in circulating concentrations of GDF11 (males 0.129 ± 0.199, females
0.114 ± 0.148 ng/mL; p = 0.986) or TSH (males 2.5 ± 2.8, females 4.4 ± 14.3 ng/mL; p = 0.794) were
observed. Interestingly, a highly significant positive correlation was found between GDF11 and TSH
levels (r = 0.40, p < 0.001) (Figure 1 and Table 2). Since GDF11 is influenced by age [13], we reassessed
the correlation analysis adjusting by age. The correlation between GDF11 and TSH levels was found
almost unchanged (r = 0.38, p < 0.001) after adjusting by age (Table 2). Moreover, a negative correlation
with age (r = −0.16, p = 0.006) and a positive one with BMI (r = 0.15, p = 0.009) and waist circumference
(r = 0.13, p = 0.029) were observed. The correlations of GDF11 with BMI and waist circumference
were conserved after adjustment by age. Neither REE (r = 0.10, p = 0.149) nor REE per unit of FFM
(REE/FFM) (r = 0.02, p = 0.725, Table 2) were significantly correlated with GDF11, while REE/FFM was
significantly correlated with leptin concentrations (r = 0.33, p < 0.001). Finally, we found significant
correlations of GDF11 levels with CRP (r = 0.19, p = 0.025) and leptin (r = 0.14, p = 0.027) levels
that were maintained after adjustment by age for both CRP (r = 0.18, p = 0.038) and leptin (r = 0.14,
p = 0.026). In the multiple linear regression analysis (Table 3), the model that best predicted logGDF11
included logTSH, leptin, BMI, age, and logCRP. This model explained 37% of the total variability of
logGDF11 concentrations (p < 0.001), with only logTSH being a significant predictor of logGDF11.
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Table 1. Demographic, biochemical, and metabolic characteristics of the individuals included in the
overall study.
All Male Female p
n 287 121 166
Age, year 50 ± 16 50 ± 17 50 ± 16 0.944
Weight, kg 101 ± 27 116 ± 26 90 ± 23 <0.001
BMI, kg/m2 36.3 ± 8.5 38.3 ± 8.1 34.8 ± 8.4 <0.001
Body fat, % 45.3 ± 8.8 41.8 ± 8.2 47.9 ± 8.4 <0.001
FFM, kg 54.0 ± 12.7 65.7 ± 9.2 45.4 ± 6.6 <0.001
FFMI, kg/m2 19.3 ± 3.1 21.7 ± 2.5 17.5 ± 2.1 <0.001
Waist circumference, cm 114 ± 20 123 ± 17 106 ± 18 <0.001
SBP, mm Hg 127 ± 18 132 ± 16 123 ± 18 <0.001
DBP, mm Hg 79 ± 11 83 ± 11 75 ± 9 <0.001
REE, kcal/d 1860 ± 421 2141 ± 355 1619 ± 309 <0.001
REE/FFM, kcal/d/kg 34.29 ± 3.77 33.92 ± 3.42 35.45 ± 3.68 <0.001
Glucose, mg/dL 104 ± 23 109 ± 24 100 ± 21 0.002
Insulin, µU/mL 15.8 ± 13.6 18.6 ± 11.3 13.8 ± 14.7 0.004
HOMA 4.3 ± 4.3 5.3 ± 4.4 3.5 ± 4.1 <0.001
Triglycerides, mg/dL 119 ± 69 137 ± 65 107 ± 70 <0.001
Total cholesterol, mg/dL 197 ± 40 192 ± 45 200 ± 35 0.150
LDL-cholesterol, mg/dL 120 ± 37 119 ± 42 120 ± 32 0.948
HDL-cholesterol, mg/dL 53.3 ± 16.4 45.7 ± 10.9 58.9 ± 17.6 <0.001
Uric acid, mg/dL 5.7 ± 1.7 6.9 ± 1.4 4.9 ± 1.3 <0.001
CRP, mg/L 8.7 ± 8.1 7.5 ± 8.54 9.6 ± 7.6 0.043
Creatinine, mg/dL 0.83 ± 0.22 0.97 ± 0.21 0.72 ± 0.16 <0.001
Leptin, ng/mL 37.3 ± 27.1 26.1 ± 16.3 45.1 ± 30.3 <0.001
TSH, µU/mL 3.6 ± 11.1 2.5 ± 2.8 4.4 ± 14.3 0.794
GDF11, ng/mL 0.121 ± 0.171 0.129 ± 0.199 0.114 ± 0.148 0.986
Data presented as mean ± SD. BMI: Body mass index; FFM: Fat-free mass; FFMI: Fat-free mass index; SBP: Systolic
blood pressure; DBP: Diastolic blood pressure; REE: Resting energy expenditure; HOMA: Homeostatic model of
assessment; CRP: C-reactive protein; TSH: Thyroid-stimulating hormone; GDF11: Growth differentiation factor
11; LDL: Low-density lipoprotein; HDL: High-density lipoprotein. Differences between groups were analyzed by
two-tailed unpaired Student’s t tests. Triglycerides, CRP, leptin, TSH, and GDF11 concentrations were logarithmically
transformed for statistical analysis due to their non-normal distribution.
We next stratified the 128 participants with thyroid profile into high (>4.7 µU/mL), normal
(0.5–4.7 µU/mL), or low (<0.5 µU/mL) TSH levels (Table 4). No significant differences in anthropometric
variables, including FFM (p = 0.797) and FFMI (p = 0.534) were observed. A significant difference
in serum total cholesterol (p = 0.018) and a tendency in LDL-cholesterol (p = 0.069) with reduced
levels in the low-TSH group were found. No other significant differences between groups were
observed except for TSH and fT4 (both p < 0.001), as expected. Subjects in the low TSH group exhibited
significantly decreased GDF11 concentrations as compared to the normal TSH group (0.068 ± 0.035 vs.
0.120 ± 0.155 ng/mL; p = 0.019) or the high TSH group (0.224 ± 0.341 ng/mL; p < 0.001) as illustrated in
Figure 2. In this subsample of 128 subjects, GDF11 and TSH levels showed again a highly significant
positive correlation (r = 0.30, p < 0.001), while no correlation was observed between GDF11 and fT4
(r = −0.06, p = 0.517) or fT3 levels (r = −0.10, p = 0.366). REE was significantly correlated with fT4 levels
(r = 0.23, p = 0.022). From the 128 patients, 23 were on L-thyroxine treatment. No effect of L-thyroxine
medication on GDF11 levels was observed (with 0.140 ± 0.287, without 0.120 ± 0.141 ng/mL; p = 0.644).
No significant differences in GDF11 concentrations were observed in patients with anti-TPO (negative
0.153 ± 0.216, positive 0.173 ± 0.274 ng/mL; p = 0.980) or anti-TG (negative 0.105 ± 0.071, positive
0.072 ± 0.033 ng/mL; p = 0.396) antibodies.
Concerning the potential relation of circulating GDF11 levels with cardiac function, no significant
differences in GDF11 concentrations were found regarding ECG (normal 0.129 ± 0.185, anomalous
0.204 ± 0.339 ng/mL; p = 0.348), hypertension (no HTA 0.124 ± 0.177, HTA 0.137 ± 0.207 ng/mL;
p = 0.567), or cardiopathy (negative 0.156 ± 0.262, positive 0.139 ± 0.152 ng/mL; p = 0.830). No
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significant correlation was observed between GDF11 levels and resting heart rate (r = −0.026, p = 0.791)
or ejection fraction (r = −0.131, p = 0.413).
Table 2. Univariate analysis of the correlation between GDF11 and other variables, unadjusted and
after adjusting for age.
Serum logGDF11
Unadjusted Correlation Adjusted Correlation
Variable r p Value r p Value
Sex −0.01 0.986 −0.04 0.995
Age −0.16 0.006 — —
Weight 0.14 0.018 0.10 0.084
BMI 0.15 0.009 0.14 0.021
Body fat 0.11 0.076 0.11 0.058
FFM 0.08 0.206 0.03 0.594
FFMI 0.10 0.094 0.08 0.212
Waist circumference 0.13 0.029 0.13 0.031
SBP 0.05 0.402 0.10 0.116
DBP 0.07 0.279 0.07 0.221
REE 0.10 0.149 0.05 0.509
REE/FFM 0.02 0.725 −0.01 0.887
Glucose 0.01 0.969 0.04 0.544
Insulin 0.07 0.278 0.06 0.304
HOMA 0.06 0.308 0.06 0.295
Triglycerides 0.03 0.629 0.04 0.487
Total cholesterol 0.05 0.407 0.06 0.298
LDL-cholesterol 0.07 0.265 0.07 0.239
HDL-cholesterol −0.05 0.367 −0.04 0.505
Uric acid 0.04 0.498 0.03 0.571
logCRP 0.19 0.025 0.18 0.038
Creatinine 0.06 0.310 0.09 0.146
Leptin 0.14 0.027 0.14 0.026
logTSH 0.40 <0.001 0.38 <0.001
Values are Pearson’s correlation coefficients and associated p values. CRP and TSH concentrations were
logarithmically transformed for statistical analysis. GDF11: Growth differentiation factor 11; BMI: Body mass
index; FFM: Fat-free mass; FFMI: Fat-free mass index; SBP: Systolic blood pressure; DBP: Diastolic blood
pressure; REE: Resting energy expenditure; HOMA: Homeostatic model assessment; CRP: C-reactive protein; TSH:
Thyroid-stimulating hormone; LDL: Low-density lipoprotein; HDL: High-density lipoprotein. For correlation with
gender, male = 1 and female = 2 was used. Bold values denote statistical significance at p < 0.05.
Table 3. Multiple regression analysis with logGDF11 as dependent variable.
Variable r2 β p Value
Model 1 0.15 <0.001
logTSH 0.397 <0.001
Model 2 0.23 <0.001
logTSH 0.462 <0.001
Leptin 0.119 0.037
Model 3 0.37 <0.001
logTSH 0.558 <0.001
Leptin 0.098 0.212
BMI 0.079 0.336
Age −0.062 0.388
logCRP 0.006 0.940
Values are corrected r2 (r2), standardized coefficients (β) and associated p values. GDF11: Growth differentiation
factor 11; TSH: Thyroid-stimulating hormone; BMI: Body mass index; CRP: C-reactive protein.
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Table 4. Demographic, biochemical, and metabolic characteristics of the individuals classified according
to TSH circulating concentrations.
High-TSH Normal-TSH Low-TSH p
n 32 76 20
Sex, M/F 11/21 31/45 6/14 0.617
Age, year 43 ± 13 45 ± 14 50 ± 8 0.142
Weight, kg 96 ± 26 97 ± 31 90 ± 21 0.612
BMI, kg/m2 34.7 ± 7.5 34.7 ± 9.7 32.0 ± 6.7 0.442
Body fat, % 43.9 ± 9.2 43.7 ± 8.8 43.1 ± 7.2 0.936
FFM, kg 52.9 ± 12.2 53.4 ± 13.9 51.2 ± 10.4 0.797
FFMI, kg/m2 19.0 ± 2.6 19.0 ± 3.4 18.1 ± 3.0 0.534
Waist circumference, cm 109 ± 19 109 ± 22 105 ± 15 0.689
SBP, mm Hg 120 ± 18 123 ± 16 118 ± 13 0.520
DBP, mm Hg 76 ± 9 76 ± 11 74 ± 8 0.712
REE, kcal/d 1713 ± 380 1799 ± 452 2007 ± 566 0.269
REE/FFM, kcal/d/kg 32.97 ± 3.76 33.71 ± 3.69 35.97 ± 3.68 0.136
Glucose, mg/dL 102 ± 30 102 ± 23 114 ± 31 0.201
Insulin, µU/mL 13.9 ± 12.0 15.4 ± 14.5 16.0 ± 10.0 0.846
HOMA 3.9 ± 4.6 4.2 ± 5.1 4.5 ± 2.8 0.907
Triglycerides, mg/dL 121 ± 70 110 ± 66 112 ± 50 0.644
Total cholesterol, mg/dL 214 ± 48 201 ± 39 178 ± 42 * † 0.018
LDL-cholesterol, mg/dL 136 ± 42 124 ± 38 109 ± 39 0.069
HDL-cholesterol, mg/dL 54.5 ± 16.4 54.8 ± 18.8 47.4 ± 11.7 0.263
Uric acid, mg/dL 5.7 ± 2.1 5.4 ± 1.7 4.7 ± 1.3 0.175
CRP, mg/L 10.9 ± 12.5 7.4 ± 7.5 5.6 ± 5.8 0.477
Creatinine, mg/dL 0.84 ± 0.23 0.79 ± 0.20 0.74 ± 0.21 0.265
Leptin, ng/mL 34.1 ± 21.7 35.1 ± 28.9 31.5 ± 26.9 0.531
TSH, µU/mL 17.3 ± 30.0 2.1 ± 1.0 * 0.2 ± 0.1* <0.001
Thyroxine (fT4), pmol/L 13.0 ± 3.8 15.8 ± 2.6 * 18.9 ± 4.1 * † <0.001
Triiodothyronine (fT3), pmol/L 2.56 ± 1.32 2.14 ± 1.14 2.05 ± 1.02 0.374
Heart rate, bpm 73 ± 14 75 ± 14 68 ± 13 0.873
Data presented as mean ± SD. BMI: Body mass index; FFM: Fat-free mass; FFMI: Fat-free mass index; SBP: Systolic
blood pressure; DBP: Diastolic blood pressure; REE: Resting energy expenditure; HOMA: Homeostatic model
assessment; CRP: C-reactive protein; TSH: Thyroid-stimulating hormone; LDL: Low-density lipoprotein; HDL:
High-density lipoprotein; bpm: Beats per minute. Differences between groups were analyzed by ANOVA followed
by LSD tests. * p < 0.05 vs. High-TSH. † p < 0.05 vs. Normal-TSH. Differences in gender distribution were analyzed
by χ2 analysis. Triglycerides, CRP, leptin, TSH, and GDF11 concentrations were logarithmically transformed for
statistical analysis due to their non-normal distribution.
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analyzed by one-way ANOVA followed by Fisher’s least significant difference (LSD) tests. * p < 0.05 
and *** p < 0.001. GDF11 concentrations were logarithmically transformed for statistical analysis due 
to their non-normal distribution. 
Table 4. Demographic, biochemical, and metabolic characteristics of the individuals classified 
according to TSH circulating concentrations. 
 High-TSH Normal-TSH Low-TSH p 
n 32 76 20  
Sex, M/F 11/21 31/45 6/14 0.617 
Age, year 43 ± 13 45 ± 14 50 ± 8 0.142 
Weight, kg 96 ± 26 97 ± 31 90 ± 21 0.612 
BMI, kg/m2 34.7 ± 7.5 34.7 ± 9.7 32.0 ± 6.7 0.442 
Body fat, % 43.9 ± 9.2 43.7 ± 8.8 43.1 ± 7.2 0.936 
FFM, kg 52.9 ± 12.2 53.4 ± 13.9 51.2 ± 10.4 0.797 
FFMI, kg/m2 19.0 ± 2.6 19.0 ± 3.4 18.1 ± 3.0 0.534 
Waist circumference, cm 109 ± 19 109 ± 22 105 ± 15 0.689 
SBP, mm Hg 120 ± 18 123 ± 16 118 ± 13 0.520 
DBP, mm Hg 76 ± 9 76 ± 11 74 ± 8 0.712 
REE, kcal/d 1713 ± 380 1799 ± 452 2007 ± 566 0.269 
REE/FFM, kcal/d/kg 32.97 ± 3.76 33.71 ± 3.69 35.97 ± 3.68 0.136 
Glucose, mg/dL 102 ± 30 102 ± 23 114 ± 31 0.201 
Insulin, μU/mL 13.9 ± 12.0 15.4 ± 14.5 16.0 ± 10.0 0.846 
HOMA 3.9 ± 4.6 4.2 ± 5.1 4.5 ± 2.8 0.907 
Triglycerides, mg/dL 121 ± 70 110 ± 66 112 ± 50 0.644 
Total cholesterol, mg/dL 214 ± 48 201 ± 39 178 ± 42 * † 0.018 
Figure 2. Serum GDF11 concentrations in subjects with high (n = 32), normal (n = 76), and low
(n = 20) concentrations of TSH. Bars represent mean ± SEM. Statistical differences between groups were
analyzed by on -way ANOVA followed by Fishe s least significant diff rence (LSD) tests. * p < 0.05
and *** p < 0.001. GDF11 concentrations were logarith ically transformed for statistical analysis due to
their non-normal distribution.
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4. Discussion
The major finding of the present study is that circulating concentrations of GDF11 are closely
associated with TSH concentrations and reduced in subjects with low TSH levels, but are apparently
unrelated to REE. Other members of the TGF-β superfamily, such as GDF15 or GDF8, have been
involved in energy homeostasis [21,22]. In the present study we observed a lack of correlation between
the circulating concentrations of GDF11 and REE, which suggest that GDF11 is not involved in energy
homeostasis. In agreement with this finding, we have previously observed that there are no differences
in serum GDF11 concentrations in obese subjects as compared to lean ones [13], although GDF11 levels
are correlated with BMI and waist circumference. It is possible that the association of GFD11 levels
with BMI may be due to its potential involvement in the regulation of skeletal muscle mass. However,
our recent findings are against this argument [13] and in the present work we have also found no
relation of GDF11 levels with FFM or FFMI as indirect surrogates of skeletal muscle mass. Larger and
interventional studies are needed to fully clarify whether or not GDF11 may play a role in energy
expenditure regulation in humans.
We have found a strong positive correlation between the serum concentrations of GDF11 and the
levels of TSH. Our work represents the first evidence of a relation between circulating levels of GDF11
and thyroid metabolism. Although correlation does not imply causality, two potential hypotheses
arise from our finding. Firstly, that TSH may be positively regulated by GDF11. In this sense, several
hormones and cytokines have been reported to affect TSH secretion. Cholecystokinin, interleukin
(IL)-1β, tumor necrosis factor (TNF)-α, and neuropeptide Y (NPY) exert inhibitory effects, while GLP-1
and leptin, among others, stimulate TSH secretion [2,23]. Although the precise pathophysiological
role of these factors remains to be elucidated, it has been suggested that they may play a role linking
the nutrition and growth status with thyroid function [2,23]. Secondly, it seems plausible that GDF11
may be positively controlled by TSH or other thyroid hormones. No evidence has been reported
regarding the effect of TSH or thyroxine on GDF11 levels or on the levels of any other GDF. TSH
stimulates the thyroid gland to secrete thyroxine but, besides its effect on the thyroid gland, TSH
also exerts actions in other tissues such as adipose tissue. In this sense, TSH has been involved in
the regulation of lipolysis in white adipose tissue as well as in the control of fuel availability for BAT
in the fasting- and cold-induced thermogenesis [3]. We did not observe different GDF11 levels in
individuals taking L-thyroxine or a positive correlation of GDF11 levels with fT4, in agreement with
previous work performed in mice [24]. Muscle dysfunction and atrophy are well known complications
of thyrotoxicosis [25]. Therefore, if GDF11 has skeletal muscle regenerating capacity, one would expect
high, rather than low, levels of GDF11 in patients with low levels of TSH, the opposite to what we
observed. Alternatively, it can be speculated that the muscle dysfunction observed with thyrotoxicosis
may be in relation with a deficient response in GDF11 secretion. Our data suggest that GDF11 is
involved in thyroid metabolism although further in vitro and in vivo studies are needed to confirm
this finding.
We observed a correlation between GDF11 levels and circulating leptin concentrations that was
maintained after adjustment by age. Furthermore, in the multiple regression model, leptin together
with TSH were significant predictors of GDF11 levels. Since GDF11 has no apparent relation with the
control of fat mass nor is it expressed by this tissue, it can be speculated that GDF11 expression could
be regulated by leptin. However, the significance of leptin as predictor of GDF11 levels was no longer
observed when BMI, age, and CRP were also included in the multiple regression model.
Initial studies suggesting a rejuvenating action for GDF11 showed that after parabiosis experiments
in mice, reversal of age-related cardiac hypertrophy was due to a blood-borne factor that was attributed
to GDF11 [26,27]. However, other reports have either failed to confirm these findings [28] or showed
important side effects of GDF11 in the heart [29]. In the present study we have observed that GDF11
levels are not related to the presence of an anomalous ECG, hypertension, or cardiopathy. Moreover,
GDF11 concentrations were not associated with resting heart rate or ejection fraction. Although higher
GDF11 levels have been associated with lower risk of cardiovascular events and death in the Heart
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and Soul Study [9] further mechanistic studies and analysis in larger cohorts are necessary to elucidate
whether or not GDF11 levels play a role in cardiovascular function.
The association of circulating concentrations of GDF11 with CRP levels suggests that this factor
may be involved in the regulation of inflammation or the acute-phase response. GDF11 expression
could be induced in response to inflammation. In this sense, it has been reported that GDF11 opposes
TNF-α-induced inflammatory actions protecting against the development of inflammatory arthritis in
mice [30]. In addition, GDF11, by inhibiting the NLRP3 inflammasome activation evidenced in vivo
and in vitro, ameliorates experimental colitis in mice [31]. Further studies aimed to assess the role of
GDF11 in inflammatory conditions will clarify this finding.
One limitation of our study is that it was performed in Caucasian individuals and it would need
to be confirmed whether our findings extend to other populations. Another limitation is that we did
not measure TSH receptor-stimulating immunoglobulins that could be influencing GDF11 secretion.
Further studies may elucidate the potential role of antibodies affecting TSH receptor in the regulation
of GDF11 levels.
In conclusion, our results show that circulating concentrations of GDF11 are closely associated with
TSH concentrations and reduced in subjects with low TSH levels. However, GDF11 is not related to the
regulation of energy expenditure. Our data also suggest that GDF11 may be involved in the regulation of
inflammation. Further studies modulating GDF11 levels and activity will undoubtedly help to elucidate
the exact role of GDF11 in metabolism and its potential involvement in thyroid pathophysiology.
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BMI body mass index
BMP bone morphogenetic protein
bpm beats per minute
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FFMI fat-free mass index
fT3 free triiodothyronine
fT4 free thyroxine
GDF8/11/15 growth differentiation factor8/11/15
GLP-1 glucagon-like peptide-1
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IL-1β interleukin-1β
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